Exciting Advancement in Acne Treatment
Cosmo Pharmaceuticals N.V. and Glenmark Pharmaceuticals Limited have made a remarkable stride in dermatological care with the regulatory approval for Winlevi® (clascoterone 10 mg/g cream) for acne treatment across several European nations.
Approval and Market Reach
The European Commission has granted Marketing Authorization, allowing mis to reach individuals suffering from acne vulgaris. This cream is specially designed for adults and adolescents aged 12 to under 18 years, intended primarily for facial use.
Following the European Medicines Agency's favorable opinion, Glenmark is set to commence the commercialization of Winlevi® in 17 European countries, including Belgium, France, Spain, and others. Both companies look forward to providing patients with this effective treatment.
Words of Leadership
Giovanni Di Napoli, the Chief Executive Officer of Cosmo, voiced enthusiasm for the collaboration with Glenmark. He remarked, "This approval shows our shared dedication to improving dermatologic care. Winlevi signifies a groundbreaking innovation in acne treatments, and we are thrilled for patients in Europe to have access to it."
Christoph Stoller, President and Business Head for Europe and Emerging Markets at Glenmark, emphasized the importance of this launch. He stated, "This approval marks a significant step in our journey to establish Glenmark as a leader in the global pharmaceutical market. Winlevi's launch in Europe bolsters our standing in the dermatology segment. We are fully committed to effective and precise launches to ensure that patients can access this treatment quickly and efficiently."
Companies Behind Winlevi®
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a globally recognized pharmaceutical company focused on research-driven innovations. Their dedication spans various therapeutic areas including respiratory, dermatology, and oncology, making them a pivotal player in the healthcare industry. With a robust infrastructure, including 11 manufacturing facilities worldwide, Glenmark continues to have a substantial impact in over 80 countries. Recently, they also received recognition for their commitment to sustainability, being the second pharmaceutical company in India to have their GHG emission reduction targets approved.
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals, headquartered in Dublin, Ireland, is a pioneering life sciences company with a focus on developing state-of-the-art solutions in MedTech AI, dermatology, and gastrointestinal diseases. Their dedication to improving healthcare is evident in their cutting-edge technologies trusted by leading pharmaceutical companies globally. Since its inception in 1997, Cosmo has been on a mission to empower patients and healthcare professionals by transforming scientific innovations into practical solutions.
Frequently Asked Questions
What is Winlevi® used for?
Winlevi® is used for the treatment of acne vulgaris in adults and adolescents aged 12 and older.
How does Winlevi® work?
Winlevi® is a topical cream that works by targeting specific pathways involved in the acne development process, providing effective treatment.
Who approved Winlevi® for use?
The European Commission granted marketing authorization for Winlevi® following a positive review by the European Medicines Agency.
In which countries will Winlevi® be available?
Winlevi® will be available in 17 European countries, including Belgium, France, and Spain, among others.
What should I know about Glenmark Pharmaceuticals?
Glenmark is a research-led pharmaceutical company known for its innovations in various fields, including dermatology, with a strong presence across multiple countries.
